

7 Literaturverzeichnis

1. Bosgraaf, L. and P.J. Van Haastert, *Roc, a Ras/GTPase domain in complex proteins*. Biochim Biophys Acta, 2003. **1643**(1-3): p. 5-10.
2. Vetter, I.R. and A. Wittinghofer, *The guanine nucleotide-binding switch in three dimensions*. Science, 2001. **294**(5545): p. 1299-304.
3. Neer, E.J., *Heterotrimeric G proteins: organizers of transmembrane signals*. Cell, 1995. **80**(2): p. 249-57.
4. Sprang, S.R., *G protein mechanisms: insights from structural analysis*. Annu Rev Biochem, 1997. **66**: p. 639-78.
5. Takai, Y., T. Sasaki, and T. Matozaki, *Small GTP-binding proteins*. Physiol Rev, 2001. **81**(1): p. 153-208.
6. Leipe, D.D., et al., *Classification and evolution of P-loop GTPases and related ATPases*. J Mol Biol, 2002. **317**(1): p. 41-72.
7. Saraste, M., P.R. Sibbald, and A. Wittinghofer, *The P-loop--a common motif in ATP- and GTP-binding proteins*. Trends Biochem Sci, 1990. **15**(11): p. 430-4.
8. Bourne, H.R., D.A. Sanders, and F. McCormick, *The GTPase superfamily: conserved structure and molecular mechanism*. Nature, 1991. **349**(6305): p. 117-27.
9. Li, G. and X.C. Zhang, *GTP Hydrolysis Mechanism of Ras-like GTPases*. Journal of Molecular Biology, 2004. **340**(5): p. 921-932.
10. Clamp, M., et al., *The Jalview Java alignment editor*. Bioinformatics, 2004. **20**(3): p. 426-427.
11. Del Villar, K., et al., *C-terminal motifs found in Ras-superfamily G-proteins: CAAAX and C-seven motifs*. Biochem Soc Trans, 1996. **24**(3): p. 709-13.
12. Khosravi-Far, R., et al., *Ras (CXXX) and Rab (CC/CXC) prenylation signal sequences are unique and functionally distinct*. J Biol Chem, 1992. **267**(34): p. 24363-8.
13. Felsenstein, J., *Inferring phylogenies from protein sequences by parsimony, distance, and likelihood methods*. Methods Enzymol, 1996. **266**: p. 418-27.
14. Thompson, J., D. Higgins, and T. Gibson, *CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice*. Nucl. Acids Res., 1994. **22**(22): p. 4673-4680.
15. Schmidt, A. and A. Hall, *Guanine nucleotide exchange factors for Rho GTPases: turning on the switch*. Genes Dev., 2002. **16**(13): p. 1587-1609.
16. Sasaki, T. and Y. Takai, *The Rho Small G Protein Family-Rho GDI System as a Temporal and Spatial Determinant for Cytoskeletal Control*. Biochemical and Biophysical Research Communications, 1998. **245**(3): p. 641-645.
17. Olofsson, B., *Rho Guanine Dissociation Inhibitors: Pivotal Molecules in Cellular Signalling*. Cellular Signalling, 1999. **11**(8): p. 545-554.
18. Scheffzek, K., et al., *The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants*. Science, 1997. **277**(5324): p. 333-8.
19. Scheffzek, K., M.R. Ahmadian, and A. Wittinghofer, *GTPase-activating proteins: helping hands to complement an active site*. Trends Biochem Sci, 1998. **23**(7): p. 257-62.
20. Andrade, M.A., C. Perez-Iratxeta, and C.P. Ponting, *Protein repeats: structures, functions, and evolution*. J Struct Biol, 2001. **134**(2-3): p. 117-31.
21. Kobe, B. and A.V. Kajava, *When protein folding is simplified to protein coiling: the continuum of solenoid protein structures*. Trends Biochem Sci, 2000. **25**(10): p. 509-15.
22. Heringa, J., *Detection of internal repeats: how common are they?* Curr Opin Struct Biol, 1998. **8**(3): p. 338-45.

23. Marcotte, E.M., et al., *A census of protein repeats*. Journal of Molecular Biology, 1999. **293**(1): p. 151-160.
24. Michaely, P. and V. Bennett, *The ANK repeat: a ubiquitous motif involved in macromolecular recognition*. Trends in Cell Biology, 1992. **2**(5): p. 127-129.
25. Sedgwick, S.G. and S.J. Smerdon, *The ankyrin repeat: a diversity of interactions on a common structural framework*. Trends in Biochemical Sciences, 1999. **24**(8): p. 311-316.
26. Mosavi, L.K., et al., *The ankyrin repeat as molecular architecture for protein recognition*. Protein Sci, 2004. **13**(6): p. 1435-1448.
27. Kobe, B. and A.V. Kajava, *The leucine-rich repeat as a protein recognition motif*. Curr Opin Struct Biol, 2001. **11**(6): p. 725-32.
28. Buchanan, S.G. and N.J. Gay, *Structural and functional diversity in the leucine-rich repeat family of proteins*. Prog Biophys Mol Biol, 1996. **65**(1-2): p. 1-44.
29. Neer, E.J., et al., *The ancient regulatory-protein family of WD-repeat proteins*. Nature, 1994. **371**(6495): p. 297-300.
30. van der Voorn, L. and H.L. Ploegh, *The WD-40 repeat*. FEBS Lett, 1992. **307**(2): p. 131-4.
31. Paoli, M., *Protein folds propelled by diversity*. Progress in Biophysics and Molecular Biology, 2001. **76**(1-2): p. 103-130.
32. Smith, T.F., et al., *The WD repeat: a common architecture for diverse functions*. Trends in Biochemical Sciences, 1999. **24**(5): p. 181-185.
33. Garcia-Higuera, I., et al., *Folding a WD Repeat Propeller. ROLE OF HIGHLY CONSERVED ASPARTIC ACID RESIDUES IN THE G PROTEIN beta SUBUNIT AND Sec13*. J. Biol. Chem., 1998. **273**(15): p. 9041-9049.
34. Cherry, M. and D.H. Williams, *Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights*. Curr Med Chem, 2004. **11**(6): p. 663-73.
35. Huse, M. and J. Kuriyan, *The conformational plasticity of protein kinases*. Cell, 2002. **109**(3): p. 275-82.
36. Hanks, S.K. and T. Hunter, *Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification*. Faseb J, 1995. **9**(8): p. 576-96.
37. Hanks, S.K., A.M. Quinn, and T. Hunter, *The protein kinase family: conserved features and deduced phylogeny of the catalytic domains*. Science, 1988. **241**(4861): p. 42-52.
38. Tagawa, H., et al., *MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8*. Oncogene, 2004. **23**(14): p. 2576-81.
39. Sakabe, T., et al., *Identification of a novel gene, MASL1, within an amplicon at 8p23.1 detected in malignant fibrous histiocytomas by comparative genomic hybridization*. Cancer Res, 1999. **59**(3): p. 511-5.
40. Bosgraaf, L., et al., *A novel cGMP signalling pathway mediating myosin phosphorylation and chemotaxis in Dictyostelium*. Embo J, 2002. **21**(17): p. 4560-70.
41. Goldberg, J.M., et al., *Identification of four candidate cGMP targets in Dictyostelium*. Proc Natl Acad Sci U S A, 2002. **99**(10): p. 6749-54.
42. Bosgraaf, L., et al., *RasGEF-containing proteins GbpC and GbpD have differential effects on cell polarity and chemotaxis in Dictyostelium*. J Cell Sci, 2005. **118**(9): p. 1899-1910.
43. Abysalh, J.C., L.L. Kuchnicki, and D.A. Larochelle, *The Identification of Pats1, a Novel Gene Locus Required for Cytokinesis in Dictyostelium discoideum*. Mol Biol Cell, 2003. **14**(1): p. 14-25.

44. Abe, T., J. Langenick, and J.G. Williams, *Rapid generation of gene disruption constructs by in vitro transposition and identification of a Dictyostelium protein kinase that regulates its rate of growth and development*. Nucleic Acids Res, 2003. **31**(18): p. e107.
45. Bettencourt-Dias, M., et al., *Genome-wide survey of protein kinases required for cell cycle progression*. Nature, 2004. **432**(7020): p. 980-987.
46. Sonnichsen, B., et al., *Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans*. Nature, 2005. **434**(7032): p. 462-469.
47. Sakaguchi, A., et al., *A C. elegans LRK-1 MAPKKK regulates polarized sorting system in neurons*. East Asia Worm Meeting, 2004. **2004**(abstract 10).
48. Nonet, M.L., et al., *Synaptic Transmission Deficits in Caenorhabditis elegans Synaptobrevin Mutants*. J. Neurosci., 1998. **18**(1): p. 70-80.
49. Harada, J.N., et al., *Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysis*. Genome Res., 2005. **15**(8): p. 1136-1144.
50. Farrer, M., et al., *LRRK2 mutations in Parkinson disease*. Neurology, 2005: p. 01.WNL.0000169023.51764.b0.
51. Di Fonzo, A., et al., *A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease*. The Lancet, 2005. **365**(9457): p. 412-415.
52. Deng, H., et al., *Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation*. Ann Neurol, 2005. **57**(6): p. 933-934.
53. Aasly, J.O., et al., *Clinical features of LRRK2-associated Parkinson's disease in central Norway*. Ann Neurol, 2005. **57**(5): p. 762-5.
54. Funayama, M., et al., *An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family*. Ann Neurol, 2005. **57**(6): p. 918-921.
55. Gilks, W.P., et al., *A common LRRK2 mutation in idiopathic Parkinson's disease*. The Lancet, 2005. **365**(9457): p. 415-416.
56. Hernandez, D.G., et al., *Clinical and positron emission tomography of Parkinson's disease caused by LRRK2*. Ann Neurol, 2005. **57**(3): p. 453-456.
57. Kachergus, J., et al., *Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations*. Am J Hum Genet, 2005. **76**(4).
58. Lesage, S., et al., *The G2019SLRRK2 Mutation in Autosomal Dominant European and North African Parkinson's Disease is Frequent and its Penetrance is Age-Dependant: LBS.003*. Neurology, 2005. **64**(10): p. 1826-b-.
59. Mata, I.F., et al., *LRRK2 R1441G in Spanish patients with Parkinson's disease*. Neuroscience Letters, 2005. **382**(3): p. 309-311.
60. Nichols, W.C., et al., *Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease*. The Lancet, 2005. **365**(9457): p. 410-412.
61. Paisan-Ruiz, C., et al., *LRRK2 gene in Parkinson disease*. Neurology, 2005: p. 01.WNL.0000167552.79769.b3.
62. Tan, E.K., et al., *The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients*. Neuroscience Letters. **In Press, Corrected Proof**.
63. Zabetian, C.P., et al., *A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations*. Neurology, 2005: p. 01.WNL.0000172630.22804.73.
64. Zimprich, A., et al., *Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology*. Neuron, 2004. **44**(4): p. 601-7.
65. Paisan-Ruiz, C., et al., *Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease*. Neuron, 2004. **44**(4): p. 595-600.
66. Brice, A., *How much does dardarin contribute to Parkinson's disease?* The Lancet, 2005. **365**(9457): p. 363-364.
67. Albrecht, M., *LRRK2 mutations and Parkinsonism*. The Lancet. **365**(9466): p. 1230.

68. Shen, J., *Protein kinases linked to the pathogenesis of Parkinson's disease*. Neuron, 2004. **44**(4): p. 575-7.
69. Toft, M., et al., *LRRK2 mutations and Parkinsonism*. The Lancet. **365**(9466): p. 1229-1230.
70. Singleton, A.B., *Altered [alpha]-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin*. Trends in Neurosciences, 2005. **28**(8): p. 416-421.
71. Bialik, S., A.R. Bresnick, and A. Kimchi, *DAP-kinase-mediated morphological changes are localization dependent and involve myosin-II phosphorylation*. Cell Death Differ, 2004. **11**(6): p. 631-44.
72. Bialik, S. and A. Kimchi, *DAP-kinase as a target for drug design in cancer and diseases associated with accelerated cell death*. Seminars in Cancer Biology, 2004. **14**(4): p. 283-294.
73. Chen, C.H., et al., *Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK*. Embo J, 2005. **24**(2): p. 294-304.
74. Tanner, C.M. and Y. Ben-Shlomo, *Epidemiology of Parkinson's disease*. Adv Neurol, 1999. **80**: p. 153-9.
75. Pardo, L.M. and C.M. van Duijn, *In search of genes involved in neurodegenerative disorders*. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. **In Press, Corrected Proof**.
76. Burch, D. and F. Sheerin, *Parkinson's disease*. The Lancet. **365**(9459): p. 622-627.
77. Bossy-Wetzel, E., R. Schwarzenbacher, and S.A. Lipton, *Molecular pathways to neurodegeneration*. Nat Med, 2004. **10** **Suppl**: p. S2-9.
78. Selkoe, D.J., *Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases*. 2004. **6**(11): p. 1054-1061.
79. Kotzbauer, P.T., et al., *Fibrillization of [alpha]-synuclein and tau in familial Parkinson's disease caused by the A53T [alpha]-synuclein mutation*. Experimental Neurology, 2004. **187**(2): p. 279-288.
80. Lewthwaite, A.J. and D.J. Nicholl, *Genetics of parkinsonism*. Curr Neurol Neurosci Rep, 2005. **5**(5): p. 397-404.
81. Huang, Y., et al., *Genetic contributions to Parkinson's disease*. Brain Research Reviews, 2004. **46**(1): p. 44-70.
82. Rocca, W.A., et al., *The prevalence of vascular dementia in Europe: facts and fragments from 1980-1990 studies*. EURODEM-Prevalence Research Group. Ann Neurol, 1991. **30**(6): p. 817-24.
83. Selkoe, D.J., *Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies*. Ann Intern Med, 2004. **140**(8): p. 627-638.
84. Fuentealba, R.A., et al., *Signal transduction during amyloid-[beta]-peptide neurotoxicity: role in Alzheimer disease*. Brain Research Reviews, 2004. **47**(1-3): p. 275-289.
85. Avila, J., et al., *Assembly in vitro of tau protein and its implications in Alzheimer's disease*. Curr Alzheimer Res, 2004. **1**(2): p. 97-101.
86. Kim, S., J.-H. Seo, and Y.-H. Suh, *[alpha]-Synuclein, Parkinson's disease, and Alzheimer's disease*. Parkinsonism & Related Disorders, 2004. **10**(Supplement 1): p. S9-S13.
87. Kamboh, M.I., *Molecular genetics of late-onset Alzheimer's disease*. Ann Hum Genet, 2004. **68**(Pt 4): p. 381-404.
88. Coleman, P., H. Federoff, and R. Kurlan, *A focus on the synapse for neuroprotection in Alzheimer disease and other dementias*. Neurology, 2004. **63**(7): p. 1155-1162.
89. Iqbal, K., et al., *Tau pathology in Alzheimer disease and other tauopathies*. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005. **1739**(2-3): p. 198-210.

90. Lander, E.S., et al., *Initial sequencing and analysis of the human genome*. Nature, 2001. **409**(6822): p. 860-921.
91. Venter, J.C., et al., *The sequence of the human genome*. Science, 2001. **291**(5507): p. 1304-51.
92. Thompson, J.D., D.G. Higgins, and T.J. Gibson, *CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice*. Nucleic Acids Res, 1994. **22**(22): p. 4673-80.
93. Blom, N., S. Gammeltoft, and S. Brunak, *Sequence and structure-based prediction of eukaryotic protein phosphorylation sites*. Journal of Molecular Biology, 1999. **294**(5): p. 1351-1362.
94. McGuffin, L.J., K. Bryson, and D.T. Jones, *The PSIPRED protein structure prediction server*. Bioinformatics, 2000. **16**(4): p. 404-405.
95. Altschul, S.F., et al., *Gapped BLAST and PSI-BLAST: a new generation of protein database search programs*. Nucleic Acids Res, 1997. **25**(17): p. 3389-402.
96. Shuman, S., *Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase*. J. Biol. Chem., 1994. **269**(51): p. 32678-32684.
97. Braman, J., C. Papworth, and A. Greener, *Site-directed mutagenesis using double-stranded plasmid DNA templates*. Methods Mol Biol, 1996. **57**: p. 31-44.
98. Sanger, F., S. Nicklen, and A.R. Coulson, *DNA sequencing with chain-terminating inhibitors*. 1977. Biotechnology, 1992. **24**: p. 104-8.
99. Warrens, A.N., M.D. Jones, and R.I. Lechler, *Splicing by overlap extension by PCR using asymmetric amplification: an improved technique for the generation of hybrid proteins of immunological interest*. Gene, 1997. **186**(1): p. 29-35.
100. Arya, M., et al., *Basic principles of real-time quantitative PCR*. Expert Rev Mol Diagn, 2005. **5**(2): p. 209-19.
101. Livak, K., *Comparative Ct method. ABI Prism 7700 Sequence Detection System*. User Bulletin no. 2. PE Applied Biosystems, 1997.
102. Fischer, G. and F.X. Schmid, *The mechanism of protein folding. Implications of in vitro refolding models for de novo protein folding and translocation in the cell*. Biochemistry, 1990. **29**(9): p. 2205-12.
103. Bradford, M.M., *A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding*. Anal Biochem, 1976. **72**: p. 248-54.
104. Pirovani, C.P., et al., *A sucrose-binding protein homologue from soybean exhibits GTP-binding activity that functions independently of sucrose transport activity*. Eur J Biochem, 2002. **269**(16): p. 3998-4008.
105. Hannon, G.J., *RNA interference*. 2002. **418**(6894): p. 244-251.
106. Elbashir, S.M., et al., *Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells*. 2001. **411**(6836): p. 494-498.
107. Hannon, G.J. and J.J. Rossi, *Unlocking the potential of the human genome with RNA interference*. 2004. **431**(7006): p. 371-378.
108. Nobes, C.D. and A. Hall, *Rho GTPases Control Polarity, Protrusion, and Adhesion during Cell Movement*. J. Cell Biol., 1999. **144**(6): p. 1235-1244.
109. Gratzner, H.G., *Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication*. Science, 1982. **218**(4571): p. 474-5.
110. Manning, G., et al., *The protein kinase complement of the human genome*. Science, 2002. **298**(5600): p. 1912-34.
111. Praefcke, G.J.K., et al., *Identification of Residues in the Human Guanylate-binding Protein 1 Critical for Nucleotide Binding and Cooperative GTP Hydrolysis*. Journal of Molecular Biology, 2004. **344**(1): p. 257-269.

112. Nolen, B., S. Taylor, and G. Ghosh, *Regulation of Protein Kinases: Controlling Activity through Activation Segment Conformation*. *Molecular Cell*, 2004. **15**(5): p. 661-675.
113. Spitaler, M., et al., *Unique structural and functional properties of the ATP-binding domain of atypical protein kinase C-iota*. *J Biol Chem*, 2000. **275**(43): p. 33289-96.
114. Zabetian, C.P., et al., *A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations*. *Neurology*, 2005. **65**(5): p. 741-744.
115. Mata, I.F., et al., *Lrrk2 pathogenic substitutions in Parkinson's disease*. *Neurogenetics*, 2005: p. 1-7.
116. Buhrman, G., V. de Serrano, and C. Mattos, *Organic Solvents Order the Dynamic Switch II in Ras Crystals*. *Structure*, 2003. **11**(7): p. 747-751.
117. Warne, P.H., P.R. Viciano, and J. Downward, *Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro*. *Nature*, 1993. **364**(6435): p. 352-5.
118. Aelst, L., et al., *Complex Formation Between RAS and RAF and Other Protein Kinases*. *PNAS*, 1993. **90**(13): p. 6213-6217.
119. Vojtek, A.B., S.M. Hollenberg, and J.A. Cooper, *Mammalian Ras interacts directly with the serine/threonine kinase Raf*. *Cell*, 1993. **74**(1): p. 205-14.
120. Jaffe, A.B. and A. Hall, *RHO GTPases: Biochemistry and Biology*. *Annu Rev Cell Dev Biol*, 2005.
121. Gaudet, R., A. Bohm, and P.B. Sigler, *Crystal structure at 2.4 angstroms resolution of the complex of transducin betagamma and its regulator, phosducin*. *Cell*, 1996. **87**(3): p. 577-88.
122. Sondek, J., et al., *Crystal structure of a G-protein beta gamma dimer at 2.1A resolution*. *Nature*, 1996. **379**(6563): p. 369-74.
123. Wall, M.A., et al., *The structure of the G protein heterotrimer Gi alpha 1 beta 1 gamma 2*. *Cell*, 1995. **83**(6): p. 1047-58.
124. Madrona, A.Y. and D.K. Wilson, *The structure of Ski8p, a protein regulating mRNA degradation: Implications for WD protein structure*. *Protein Sci*, 2004. **13**(6): p. 1557-1565.
125. Wilson, D.K., D. Cerna, and E. Chew, *The 1.1-angstrom structure of the spindle checkpoint protein Bub3p reveals functional regions*. *J Biol Chem*, 2005. **280**(14): p. 13944-51.
126. Bokoch, G.M., *BIOLOGY OF THE P21-ACTIVATED KINASES*. *Annual Review of Biochemistry*, 2003. **72**(1): p. 743-781.
127. Schwartz, M., *Rho signalling at a glance*. *J Cell Sci*, 2004. **117**(23): p. 5457-5458.
128. Burridge, K. and K. Wennerberg, *Rho and Rac Take Center Stage*. *Cell*, 2004. **116**(2): p. 167-179.
129. Etienne-Manneville, S. and A. Hall, *Rho GTPases in cell biology*. *Nature*, 2002. **420**(6916): p. 629-35.
130. Wennerberg, K. and C.J. Der, *Rho-family GTPases: it's not only Rac and Rho (and I like it)*. *J Cell Sci*, 2004. **117**(8): p. 1301-1312.
131. Johnson, L.N., M.E. Noble, and D.J. Owen, *Active and inactive protein kinases: structural basis for regulation*. *Cell*, 1996. **85**(2): p. 149-58.
132. Tokui, T., S. Ando, and M. Ikebe, *Autophosphorylation of smooth muscle myosin light chain kinase at its regulatory domain*. *Biochemistry*, 1995. **34**(15): p. 5173-9.
133. Griffith, L.C., C.S. Lu, and X.X. Sun, *CaMKII, an Enzyme on the Move: Regulation of Temporospatial Localization*. *Mol. Interv.*, 2003. **3**(7): p. 386-403.
134. Colbran, R.J. and A.M. Brown, *Calcium/calmodulin-dependent protein kinase II and synaptic plasticity*. *Current Opinion in Neurobiology*, 2004. **14**(3): p. 318-327.

135. Renault, L., et al., *The 1.7[Å] crystal structure of the regulator of chromosome condensation (RCC1) reveals a seven-bladed propeller*. Nature, 1998. **392**(6671): p. 97-101.
136. Li, W., M. Han, and K.-L. Guan, *The leucine-rich repeat protein SUR-8 enhances MAP kinase activation and forms a complex with Ras and Raf*. Genes Dev., 2000. **14**(8): p. 895-900.
137. Ross, O.A. and M.J. Farrer, *Pathophysiology, pleiotropy and paradigm shifts: genetic lessons from Parkinson's disease*. Biochem Soc Trans, 2005. **33**(Pt 4): p. 586-90.
138. Blacker, D., et al., *Results of a high-resolution genome screen of 437 Alzheimer's Disease families*. Hum. Mol. Genet., 2003. **12**(1): p. 23-32.
139. Frasier, M. and B. Wolozin, *Following the leader: fibrillization of [alpha]-synuclein and tau*. Experimental Neurology, 2004. **187**(2): p. 235-239.
140. Wenning, G.K. and K.A. Jellinger, *The role of alpha-synuclein and tau in neurodegenerative movement disorders*. Curr Opin Neurol, 2005. **18**(4): p. 357-62.
141. Ishizawa, T., et al., *Colocalization of tau and alpha-synuclein epitopes in Lewy bodies*. J Neuropathol Exp Neurol, 2003. **62**(4): p. 389-97.
142. Popescu, A., et al., *Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions*. Arch Neurol, 2004. **61**(12): p. 1915-9.
143. Giasson, B.I., et al., *Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein*. Science, 2003. **300**(5619): p. 636-640.
144. Cozier, G.E., et al., *Membrane targeting by pleckstrin homology domains*. Curr Top Microbiol Immunol, 2004. **282**: p. 49-88.
145. Musacchio, A., et al., *The PH domain: a common piece in the structural patchwork of signalling proteins*. Trends Biochem Sci, 1993. **18**(9): p. 343-8.